DEA Revokes John Hanley, P.A.’s Registration in New Mexico Estimated reading time: 1–7 minutes The Drug Enforcement Administration (DEA) has revoked the Certificate of Registration No. MH4317702 held by John Hanley, P.A. of Santa Fe, New Mexico. The order was published in the Federal Register on July 9, 2025. Reason for Revocation According to the DEA, John Hanley is not allowed to prescribe, dispense, or handle controlled substances in New Mexico. His registration was revoked because he does not have the required state license. The New Mexico Medical Board had revoked Hanley’s physician assistant license on or about February 27, 2024. Service of Notice The DEA attempted to contact Hanley at his last known home address. When they could not deliver the notice in person, the DEA emailed a copy of the Order to Show Cause to Hanley’s registered email address. The email was confirmed as delivered. Lack of Response and Default Hanley did not reply to the DEA’s Order to Show Cause. He did not request a hearing. Under DEA rules, if a registrant does not respond, it is considered a default. The person loses the right to a hearing. The allegations are then taken as true. Findings The DEA confirmed that Hanley is not licensed to practice as a physician assistant in New Mexico. This is based on the state’s online records. Legal Basis The Controlled Substances Act requires that anyone registered to handle controlled substances must be licensed in the state where they practice. If a state license is lost or revoked, the DEA must also revoke its registration. In New Mexico, a physician assistant must be licensed by the New Mexico Medical Board to prescribe or handle controlled substances. Without that state license, Hanley cannot legally work as a physician assistant or dispense controlled substances in New Mexico. Order Details The DEA has revoked John Hanley’s registration. The agency has also denied any ongoing or future applications to renew or modify his registration in New Mexico. This order becomes effective on August 8, 2025. Signing Authority The order was signed on July 2, 2025, by Acting Administrator Robert J. Murphy. Heather Achbach, Federal Register Liaison Officer, confirmed the document for publication. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Texas Doctor Andrew Jones, M.D.’s Controlled Substance Registrations Estimated reading time: 5–8 minutes On December 9, 2024, the Drug Enforcement Administration (DEA) sent an Order to Show Cause to Andrew Jones, M.D. of Houston, Texas. The DEA threatened to revoke his DEA Certificate of Registration numbers FJ3614826 and FJ9984154. The reason was that Dr. Jones no longer had the authority to prescribe, give out, or handle controlled substances in the state of Texas, where he was registered. Dr. Jones asked for a hearing and gave a Supplemental Answer. Later, the Government filed a Motion for Summary Disposition. Dr. Jones responded and supplied evidence. On February 11, 2025, Administrative Law Judge Teresa A. Wallbaum granted the Government’s Motion. She said Dr. Jones did not have Texas state authority to handle controlled substances. The judge said there was “no genuine issue of material fact in this case.” Dr. Jones did not file any exceptions to the judge’s recommended decision. The DEA reviewed the record and agreed with the judge’s findings. The DEA said it would take official notice that, on or about April 4, 2024, the Texas Medical Board temporarily restricted Dr. Jones’s medical license. Dr. Jones is not allowed to possess, give out, or prescribe controlled substances in Texas. State online records confirm that Dr. Jones’s license is active but remains restricted. The DEA explained that, by law, a practitioner must have state authority to handle controlled substances. If a doctor loses this authority, they cannot have a DEA registration. This rule is based on the Controlled Substances Act. The law says a practitioner must be licensed, registered, or allowed by the state to handle controlled substances. Without this, a doctor cannot prescribe or give out such drugs. According to the Texas law, “dispense” means delivering or prescribing a controlled substance as part of professional practice. Only practitioners licensed or otherwise allowed in Texas can do this. Since Dr. Jones lost his authority, he does not qualify for a DEA registration in Texas. As a result, the DEA has revoked Dr. Jones’s DEA Certificate of Registration numbers FJ3614826 and FJ9984154. The DEA also denied any pending applications from Dr. Jones to renew or change these registrations. Any other requests for registration by Dr. Jones in Texas are also denied. The order will be effective August 8, 2025. This order was signed by Acting Administrator Robert J. Murphy of the DEA on July 1, 2025. The document was submitted for publication by Heather Achbach, DEA Federal Register Liaison Officer. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Dr. Hayriye Gok’s Registration to Handle Controlled Substances in Pennsylvania Estimated reading time: 3–5 minutes On July 9, 2025, the Drug Enforcement Administration (DEA) announced it has revoked the Certificate of Registration for Hayriye Gok, M.D., of Philadelphia, Pennsylvania. This certificate allowed Dr. Gok to handle controlled substances in the state. The action came after the DEA issued an Order to Show Cause (OSC) against Dr. Gok on February 20, 2025. The DEA stated that Dr. Gok could not legally handle controlled substances in Pennsylvania because her state license to practice medicine had been suspended. Dr. Gok was notified about the OSC and was informed she had the right to ask for a hearing. She did not request a hearing. According to the DEA, when a person does not ask for a hearing, they are considered to have admitted the facts listed in the OSC. The DEA tried to reach Dr. Gok at her business address and by phone, but was not successful. The DEA then served the OSC to Dr. Gok by email. Dr. Gok replied and confirmed she received the notice, but she still did not ask for a hearing. The DEA checked Pennsylvania’s official online license records. As of the date of the order, Dr. Gok’s medical license showed a “Suspension” status. The Pennsylvania State Board of Medicine had temporarily suspended her license on November 21, 2024. The DEA orders are based on federal law. This law says that a physician must have a valid state license to get and keep a DEA registration to dispense controlled substances. Without a license, a doctor is not allowed to prescribe, administer, or handle these drugs. In Pennsylvania, a practitioner must be licensed or otherwise allowed to give out or prescribe a controlled substance. With Dr. Gok’s license suspended, she is not allowed to practice medicine or handle controlled substances in Pennsylvania. The DEA’s order also says that any pending applications by Dr. Gok to renew or change her registration, or to get a new registration in Pennsylvania, are denied. The DEA’s action is final and goes into effect on August 8, 2025. The order was signed by Acting Administrator Robert J. Murphy on July 1, 2025, and published in the Federal Register. Heather Achbach, the DEA Federal Register Liaison Officer, completed the filing for official publication. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Announces Proposed Consent Decree With Trialco Aluminum, LLC Estimated reading time: 3–5 minutes On July 2, 2025, the Department of Justice (DOJ) lodged a proposed Consent Decree with the United States District Court for the Northern District of Illinois. The case is called United States v. Trialco Aluminum, LLC, Civil Action No. 1:25-cv-07461. This Consent Decree tries to resolve claims against Trialco Aluminum, LLC. The claims are about the company’s emissions of hazardous air pollutants at its aluminum production facility. This facility is located in Chicago Heights, Illinois. The complaint in this case asks for both injunctive relief and civil penalties. It is brought under Section 113(b) of the Clean Air Act (CAA), which is 42 U.S.C. 7413(b). It claims that Trialco violated two sets of rules: The National Emission Standards for Hazardous Pollutants (NESHAP) for secondary aluminum production facilities, found in 40 CFR part 63, subpart RRR. The facility’s Federally Enforceable State Operating Permit (FESOP) for its Chicago Heights location. According to the proposed Consent Decree, Trialco Aluminum, LLC will do several things: Pay a civil penalty of $1 million. Do an updated assessment of its capture and collection system for emissions. Adopt and use a new Operation, Maintenance, and Monitoring (OM&M) plan. Apply for a new FESOP, which must include revised operating limits. The DOJ has opened a public comment period for this Consent Decree. Comments should be sent to the Assistant Attorney General, Environment and Natural Resources Division. All comments must refer to United States v. Trialco Aluminum, LLC, D.J. Ref. No. 90-5-2-1-12888. The deadline to submit comments is 30 days after this notice was published. Comments can be sent by email or mail: By email: [email protected] By mail: Assistant Attorney General, U.S. DOJ–ENRD, P.O. Box 7611, Washington, DC 20044-7611. Any comment sent in writing, or at a public meeting, may be filed in the public court docket without giving notice to the commenter. During the public comment period, the full Consent Decree can be read and downloaded from the DOJ’s website at http://www.justice.gov/enrd/consent-decrees. If help is needed to access the Consent Decree, assistance can be requested using the same email or mail address as for comments. This notice was signed by Laura Thoms, Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. For further details, see Federal Register Volume 90, Number 129, published on July 9, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Ohio Doctor Loretta Clement’s Registration to Handle Controlled Substances Estimated reading time: 3–5 minutes The Drug Enforcement Administration (DEA) has revoked the Certificate of Registration No. FC2337500 for Loretta Clement, M.D., of Cincinnati, Ohio. Dr. Clement is now barred from prescribing, administering, dispensing, or otherwise handling controlled substances in Ohio. The DEA issued an Order to Show Cause (OSC) to Dr. Clement on February 18, 2025. The order said her registration should be revoked because she does not have the legal authority to prescribe controlled substances in Ohio. She did not request a hearing about this order. The DEA confirmed the OSC was sent to Dr. Clement by email after attempts to serve her at her home and offices failed. The DEA Diversion Investigator spoke with Dr. Clement by phone and explained the process. The State Medical Board of Ohio suspended Dr. Clement’s license on or about August 14, 2024. The agency checked the official Ohio state records and confirmed that Dr. Clement’s medical license is inactive. Dr. Clement may dispute this fact by filing a motion within fifteen days of the order. DEA rules say that a doctor must have state authority to prescribe controlled substances in order to have a DEA registration. When a doctor loses that authority, the DEA is allowed to revoke the registration. Under Ohio law, only doctors with a valid license may prescribe or handle these medicines. Because Dr. Clement’s medical license is not active, she is not allowed to prescribe or handle controlled substances in Ohio. The DEA therefore ordered her registration revoked. The decision was signed on July 1, 2025, by Acting Administrator Robert J. Murphy. The order takes effect August 6, 2025. Any new or pending applications by Dr. Clement to renew, modify, or add DEA registration in Ohio are denied. This notice was published in the Federal Register, Volume 90, Number 127, pages 29885-29886, on July 7, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Medical License of Loretta Clement, M.D. Estimated reading time: 2–4 minutes Background On February 18, 2025, the DEA sent an Order to Show Cause to Dr. Clement. This order explained that her registration would be revoked. The reason was that Dr. Clement could no longer prescribe, handle, or dispense controlled substances in Ohio. This is because she does not have a valid medical license in the state. Dr. Clement did not ask for a hearing about this decision. The DEA mailed and emailed the order to her. She did not reply. The DEA investigator also called Dr. Clement and explained the process. Because she did not respond, the DEA counted her as “in default.” In such cases, the Agency admits the government’s facts as true. Findings In August 2024, the State Medical Board of Ohio suspended Dr. Clement’s license to practice medicine. The DEA checked the State of Ohio’s license database. Her license is listed as inactive. This means, as of July 2025, Dr. Clement cannot work as a doctor in Ohio. Legal Basis Federal law says a doctor must have a valid state license to handle controlled drugs. Once Dr. Clement’s state license was suspended, she could not legally prescribe or handle those substances. The DEA must revoke registration when a doctor does not have this state authority. Ohio law also requires any person prescribing drugs to be authorized under state law. Only doctors with valid licenses are allowed to prescribe or administer controlled substances. Dr. Clement’s suspension means she is no longer authorized to do this. Order and Next Steps DEA Acting Administrator Robert J. Murphy signed the order on July 1, 2025. The order revokes Dr. Clement’s DEA Certificate of Registration, number FC2337500. It also denies any current or future applications by Dr. Clement to renew or modify her registration, or to gain new registrations in Ohio. The order will take effect on August 6, 2025. Official Filing The notice was filed with the Federal Register by Heather Achbach, Federal Register Liaison Officer for the DEA. The DEA’s actions follow all guidelines in the law and DEA regulations. End of Notice Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Announces Intent to Temporarily Schedule Seven Benzimidazole-Opioids as Schedule I Substances Estimated reading time: 5–6 minutes Background The Drug Enforcement Administration (DEA) plans to temporarily place seven benzimidazole-opioids into Schedule I of the Controlled Substances Act (CSA). This move follows concerns that these synthetic opioids pose an imminent danger to public safety. Ethyleneoxynitazene Methylenedioxynitazene (also called 3′,4′-methylenedioxynitazene) 5-methyl etodesnitazene N-desethyl etonitazene N-desethyl protonitazene N,N-dimethylamino etonitazene N-pyrrolidino isotonitazene When the temporary scheduling order is published after July 28, 2025, these substances will be subject to all regulations, civil, and criminal penalties applicable to Schedule I controlled substances. Legal Framework Under 21 U.S.C. 811(h), the DEA may schedule substances temporarily for two years if it is necessary to avoid an imminent hazard to public safety. This can be extended for up to one year if certain proceedings are initiated. A substance can only be temporarily scheduled in Schedule I if it is not already scheduled elsewhere, and if there is no FDA approval for its medical use. According to the DEA and Health and Human Services (HHS), none of these seven substances are approved for medical use in the United States. History and Pattern of Abuse Benzimidazole-opioids were first created in the 1950s for pain relief but were never approved for medical use. Since 2019, these opioids—also called “nitazenes”—started showing up in illegal drug markets in the U.S. They are usually found as powders or tablets, often mixed with other drugs. These substances have been linked to a growing number of overdose deaths. Reports have found them in both drug seizures and in biological samples from fatal cases. Current Abuse and Law Enforcement Encounters Since 2023, there have been 184 reports related to these seven substances in the National Forensic Laboratory Information System (NFLIS-Drug) database. Here are the reported state encounters: Ethyleneoxynitazene: 14 encounters in 5 states Methylenedioxynitazene: 19 encounters in 5 states 5-methyl etodesnitazene: 4 encounters in 1 state N-desethyl etonitazene: 114 encounters in 14 states N-desethyl protonitazene: 9 encounters in 6 states N,N-dimethylamino etonitazene: 12 encounters in 4 states N-pyrrolidino isotonitazene: 12 encounters in 9 states These drugs are often abused along with other powerful substances such as fentanyl, heroin, or designer benzodiazepines. Public Health Risks These benzimidazole-opioids act like other strong opioids, affecting mu-opioid receptors in the brain. They can cause serious health effects, including respiratory depression and death. In 2024, these substances were found in at least 37 toxicology cases. They have no accepted medical use. People who use drugs from unknown sources may be at higher risk since the exact content and strength are uncertain. The spread of these substances makes the ongoing opioid crisis even worse. Regulatory Process and Next Steps The DEA followed all legal steps: Gave notice to the HHS, who did not object. Is giving the public 30 days’ notice before the order is published. Once the temporary order is in effect, these seven substances will: Be illegal to make, distribute, or possess except as allowed by law. Be regulated with the same controls as other Schedule I substances. This action will last for two years, with the possibility of a one-year extension as DEA works on permanent scheduling rules. Federal Rulemaking Temporary scheduling is issued as an “order” and not a “rule.” Regular rulemaking, which takes longer and allows more public input, will continue to determine if these drugs should be permanently scheduled. Summary Table of Scheduled Substances Substance DEA Code Ethyleneoxynitazene 9770 Methylenedioxynitazene 9766 5-methyl etodesnitazene 9767 N-desethyl etonitazene 9768 N-desethyl protonitazene 9769 N,N-dimethylamino etonitazene 9771 N-pyrrolidino isotonitazene 9772 Authority This action was signed on June 17, 2025, by Acting DEA Administrator Robert J. Murphy. For more details, the public can review the full notice and supporting material under Docket Number DEA-1494 at www.regulations.gov. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Bohdan Olesnicky, M.D.’s Certificate to Handle Controlled Substances in California Estimated reading time: 2–3 minutes On June 26, 2025, the Drug Enforcement Administration (DEA) published a decision and order to revoke the Certificate of Registration No. FO0628391 for Bohdan Olesnicky, M.D., of Indian Wells, California. The DEA took action because Dr. Olesnicky does not have authority to handle controlled substances in California. On December 5, 2023, Dr. Olesnicky surrendered his California physician’s and surgeon’s license. The DEA explained that holding a valid state license is required to handle controlled substances. The DEA cited the Controlled Substances Act, which says a practitioner must be authorized by the state to dispense controlled substances. The DEA stated that California law requires a “practitioner” to be licensed to distribute, dispense, or handle controlled substances. Since Dr. Olesnicky is no longer licensed in California, he is not allowed to handle these substances in the state. The DEA made efforts to notify Dr. Olesnicky about the action. On November 15, 2024, the DEA left a copy of the Order to Show Cause (OSC) at Dr. Olesnicky’s address. They also tried to contact him by email and certified mail. The DEA found these steps met the legal requirements for giving notice. Dr. Olesnicky did not respond to these notices or request a hearing. According to DEA rules, this is treated as a waiver of his right to a hearing and as an admission of the facts in the order. Because Dr. Olesnicky is no longer allowed to practice medicine in California, the DEA ordered the following: The Certificate of Registration No. FO0628391 for Dr. Olesnicky is revoked. Any applications to renew or change this registration are denied. Any other application for a DEA registration in California by Dr. Olesnicky is denied. This order becomes effective July 28, 2025. The decision was signed by Acting Administrator Robert J. Murphy on June 20, 2025, and published in the Federal Register. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Revokes Seattle Nurse Practitioner’s Registration for Violating Controlled Substances Laws Estimated reading time: 4–6 minutes On June 26, 2025, the Drug Enforcement Administration (DEA) published an official notice revoking the DEA Certificate of Registration for Scott Hansen, A.P.R.N., a nurse practitioner based in Seattle, Washington. This action follows a series of violations concerning controlled substances and failure to maintain proper state licensing. Immediate Suspension and Order to Show Cause On July 18, 2024, the DEA issued an Order to Show Cause and Immediate Suspension of Registration (OSC/ISO) to Scott Hansen. The order stated that Hansen’s DEA registration, No. MH7100124, was suspended under federal law because his continued registration posed “an imminent danger to the public health or safety.” The DEA also proposed revocation of Hansen’s registration, stating that his conduct was inconsistent with the public interest and that he no longer had state authority to handle controlled substances in Washington State, where he was registered. Prescriptions Written After License Suspension According to the DEA, Hansen prescribed at least five controlled substances after his Washington advanced registered nurse practitioner (ARNP) license was indefinitely suspended by the Washington State Board of Nursing on March 5, 2024. Hansen issued prescriptions for medications including amphetamine/dextroamphetamine, lisdexamfetamine, oxycodone/acetaminophen, and buprenorphine between March 19 and April 19, 2024, during which he did not have a valid ARNP license. Violation of State and Federal Law Federal law requires registrants to be authorized to dispense controlled substances under the laws of the state in which they practice. Washington law mandates that only a licensed ARNP may prescribe or deliver controlled substances, and unlicensed practice is unlawful. The DEA found Hansen lacked state authority to practice and therefore was not eligible to maintain his DEA registration. Writing prescriptions while unlicensed violated the Controlled Substances Act and Washington state law. Notification and Service The DEA made multiple attempts to serve the OSC/ISO to Hansen, including visiting his registered and mailing addresses, contacting the realtor involved in the sale of Hansen’s house, and attempting to reach him by phone, voicemail, text, and email. The DEA determined that Hansen was successfully served by email. Hansen did not request a hearing nor respond to the allegations. Grounds for Revocation According to the DEA, there are two main grounds for revocation: Hansen lost his state authority to handle controlled substances when his ARNP license was suspended. Hansen’s continued registration was inconsistent with the public interest because of repeated violations, including prescribing without state authorization. The DEA found that these actions were outside the usual course of professional practice and were not for a legitimate medical purpose. Public Interest Consideration The Controlled Substances Act requires DEA registrants to comply with strict rules to help control drug abuse and trafficking. Hansen’s actions, issuing prescriptions without proper state licensing, went against these principles. The DEA weighed all required public interest factors and determined that Hansen’s violations, along with his failure to respond or take responsibility, provided a strong basis for revocation. Order Effective July 28, 2025 The DEA revoked Scott Hansen’s DEA Certificate of Registration, No. MH7100124, effective July 28, 2025. The DEA also denied any of Hansen’s pending applications for renewal, modification, or additional registrations for controlled substances in Washington. The order was signed by Acting Administrator Robert J. Murphy on June 20, 2025, and officially published in the Federal Register. Contact Information Any challenges to the DEA’s findings can be filed within fifteen calendar days of the order. Reference Federal Register Volume 90, Number 121 (Thursday, June 26, 2025), Pages 27338-27341, Document Number 2025-11731. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

National Institute of Corrections Advisory Board Schedules Public Meeting for July 15, 2025 Estimated reading time: 1–7 minutes The National Institute of Corrections (NIC) Advisory Board will hold a meeting on Tuesday, July 15, 2025. This meeting will take place virtually. The public session is from 1:00 p.m. to 4:00 p.m. Eastern Time. A closed session will follow from 4:00 p.m. to 4:30 p.m. Eastern Time. The NIC Advisory Board helps NIC make long-range plans. The board gives advice on program development. They guide NIC on training, technical help, information services, and policy development. These services support corrections agencies at the federal, state, and local levels. Leslie LeMaster is the Designated Federal Officer for the meeting. NIC is located at 320 First Street NW, Room 901-3, Washington, DC 20534. You can call Ms. LeMaster at (202) 305-5773 or email her for more information. On July 15, the board will hear a report from the NIC Director. Each division of NIC will also give updates about their projects. There will be time for board members to ask questions and share guidance. The public can join the meeting virtually. People can offer their ideas and comments in person or in writing. Requests to join and present must be submitted to Ms. LeMaster by Monday, July 7, 2025. There is a public comment period from 3:35 p.m. to 3:50 p.m. Each person or group will have a limited amount of time to speak. People who want to present should give the topic, names, titles, agencies, addresses, emails, and the time needed by July 7, 2025. The session from 4:00 p.m. to 4:30 p.m. will be closed. This part is private so that the board can discuss internal personnel rules and practices or personal information, as allowed by law. NIC will try to help everyone attend the meeting. If you need special help due to a disability, contact Leslie LeMaster by July 7, 2025. This notice follows the Federal Advisory Committee Act (5 U.S.C. app. 2). Leslie LeMaster is listed as the contact person and the Designated Federal Officer for the National Institute of Corrections. The official notice was filed on June 25, 2025. The meeting is announced in accordance with legal requirements. The billing code for this notice is 4410-36-P. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Rust Foundation Updates Membership in National Research Venture Estimated reading time: 2–4 minutes On May 27, 2025, the Rust Foundation made official notifications with the Attorney General and the Federal Trade Commission. These notifications were made under section 6(a) of the National Cooperative Research and Production Act of 1993. The law is found in 15 U.S.C. 4301 et seq. The notifications shared new changes in group membership. Five new parties have joined the Rust Foundation’s research project. They are: Fledgio Limited, London, UNITED KINGDOM OpenAtom Foundation, Beijing, PEOPLE’S REPUBLIC OF CHINA School of Computer Science at University of Bristol, Bristol, UNITED KINGDOM Stichting Trifecta Tech Foundation, Nijmegen, KINGDOM OF THE NETHERLANDS Tock Foundation, Seattle, WA Three organizations have withdrawn as parties in the project. They are: Dropbox Inc., San Francisco, CA Embecosm, Southampton, UNITED KINGDOM Knoldus Inc., Missisauga, CANADA No other changes have taken place in either the membership or planned work of the research group. The membership in the group research project continues to stay open. The Rust Foundation will send more written notifications when new members join or leave. The Rust Foundation first filed a notification for this venture on April 14, 2022. The Department of Justice published notice of that filing in the Federal Register on May 13, 2022 (87 FR 29384). The most recent notification before this was filed on March 19, 2025. Notice of that was published in the Federal Register on April 21, 2025 (90 FR 16702). This information was filed by Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division, at the Department of Justice. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Notice of ASTM International Filing Published in the Federal Register Estimated reading time: 1–3 minutes On June 20, 2025, the Department of Justice announced an official notice from ASTM International. This notice appears in Volume 90, Number 117 of the Federal Register, on page 26328. The notice states that ASTM International has filed written notifications as of May 22, 2025. The filing is under section 6(a) of the National Cooperative Research and Production Act of 1993, found at 15 U.S.C. 4301 et seq., also known as “the Act.” ASTM International sent these notifications to both the Attorney General and the Federal Trade Commission. The purpose of the notification is to extend the protections in the Act. These protections limit what antitrust plaintiffs can recover to only actual damages under specific situations. The content of the filing from ASTM International contains an updated list of ongoing standards development activities. These activities are called “Work Items,” and they started between February 17, 2025, and May 13, 2025. Each Work Item has a brief description and is listed on the ASTM website at http://www.astm.org. ASTM International first filed a notification for these purposes on September 15, 2004. The Department of Justice then published a notice about it in the Federal Register on November 10, 2004, found at 69 FR 65226. The most recent prior notification from ASTM was filed on February 28, 2025. That notice appeared in the Federal Register on April 21, 2025, at 90 FR 16701. Suzanne Morris, Deputy Director of Civil Enforcement Operations at the Antitrust Division, certified this notice. The document’s reference number is 2025-11311. It was filed on June 18, 2025, at 8:45 am. The Department of Justice Antitrust Division’s billing code for this notice is 4410-11-P. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

AJNA Biosciences Applies to Make Psilocybin and Psilocyn in Colorado Estimated reading time: 2–3 minutes What AJNA Wants to Do AJNA Biosciences wants to make mushrooms that contain Psilocybin and Psilocyn. These are both schedule I controlled substances. The company’s work is for internal research, clinical trials, and analysis. AJNA also wants to sell these substances to its customers who do schedule I clinical research. Where and When AJNA Biosciences is located at 8022 Southpark Circle, Suite 500, Littleton, Colorado 80120-5659. The company sent its application on May 7, 2025. Rules and Details The DEA says this notice is made under 21 CFR 1301.33(a). Anyone who is a registered bulk manufacturer or an applicant for the same substances can comment or object. They have until August 18, 2025, to do this. They may also ask for a hearing by the same date. How to Comment Comments need to be sent electronically through the Federal eRulemaking Portal at https://www.regulations.gov. People can write short comments or attach longer files. After sending a comment, a Comment Tracking Number is given. Comments may not show up right away on the site. Who Signed the Notice Matthew Strait, Deputy Assistant Administrator at the DEA, signed the notice. No activities except for those listed are allowed for this registration. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Posts Notice on NFPA Standards Activity Estimated reading time: 3–5 minutes The Department of Justice has published an official notice in the Federal Register on June 13, 2025. This notice is about the National Fire Protection Association (NFPA) and its work on developing safety standards. On May 1, 2025, the NFPA filed written notifications under section 6(a) of the National Cooperative Research and Production Act of 1993. The NFPA sent this notice to the Attorney General and the Federal Trade Commission. This is part of their regular process when updating their standards development activities. The NFPA’s filing is meant to extend the protection of the Act. This Act limits the recovery of antitrust damages to actual damages in certain situations. The NFPA has sent an updated list about its standards development. This includes information on their technical committees and assessment work. The NFPA releases information about its regulations, current standards, standards development, and assessment activities to the public. This information is available on the NFPA website at nfpa.org. The NFPA first notified the Department of Justice under this Act on September 20, 2004. The first notice was published in the Federal Register on October 21, 2004. The most recent notification before this one was filed on January 24, 2025. That notice was published on February 28, 2025. Suzanne Morris, Deputy Director of Civil Enforcement Operations at the Antitrust Division, signed this latest notice. The notice was printed under [FR Doc. 2025-10768]. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

New Venture on Electrified Vehicle and Energy Storage Announced Estimated reading time: 3–5 minutes On April 3, 2025, a notice was filed with the Department of Justice Antitrust Division. It is about Electrified Vehicle and Energy Storage Evaluation–II (EVESE II). This notice is under the National Cooperative Research and Production Act of 1993. The purpose is to let the public know which companies are working together, and what the group intends to do. The notice lists the parties in the EVESE II venture. These are: BAE Systems Controls Inc., from Endicott, New York Castrol Limited, from Reading, United Kingdom Ford Motor Company, from Dearborn, Michigan Honda Development & Manufacturing of America, LLC, from Marysville, Ohio Komatsu America Corp, from Chicago, Illinois The companies plan to better understand battery energy storage systems. This work is for vehicles and other uses. They will study batteries in both normal use (called cycling) and in unusual or extreme use (called abuse). The research will focus on three main areas. These are: the battery cell, the battery module, and applications of the battery. The notice says this information is being made public to limit damages if there are any antitrust lawsuits. The Deputy Director for Civil Enforcement Operations in the Antitrust Division, Suzanne Morris, signed the notice. This entry is documented in the Federal Register, Volume 90, Number 113, Page 25081. The filing date was June 12, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Announces Updates to NPSS Cooperative Research Group Estimated reading time: 2–3 minutes On May 7, 2025, the Southwest Research Institute’s Cooperative Research Group on Numerical Propulsion System Simulation (NPSS) submitted a notice to the Department of Justice and the Federal Trade Commission. This was done under section 6(a) of the National Cooperative Research and Production Act of 1993. The notice reported changes in the group’s membership. Mitsubishi Power Aero, LLC, based in Glastonbury, Connecticut, has been added as a new member of the NPSS group. The notice also said that the period for the group’s work has been extended. The new end date for the research group’s project is now April 30, 2026. No other changes were made to the group’s membership or activities. The NPSS group is still accepting new members and plans to report any future changes as required. NPSS first filed for protection under the Act on December 11, 2013. A notice about this was published in the Federal Register on February 20, 2014. The latest notice before this one was filed with the Department of Justice on October 29, 2024. That notice was published on January 24, 2025, in the Federal Register. Suzanne Morris, Deputy Director of Civil Enforcement Operations in the Antitrust Division, signed the notice. This information can be found in the Federal Register, Volume 90, Number 113, on Friday, June 13, 2025. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

New Members Join Global Synchronizer Foundation Estimated reading time: 2–4 minutes On June 13, 2025, the Department of Justice published a notice in the Federal Register about changes in the Global Synchronizer Foundation (GSF). This notice is made under the National Cooperative Research and Production Act of 1993. GSF sent written notifications to both the Attorney General and the Federal Trade Commission. These notifications let the government know that four new members have joined the group. The new members are Proof Group from Menlo Park, California; T-RIZE Group from Montreal, Canada; Chainlink Labs from New York, New York; and BNP Paribas from Paris, French Republic. This update was filed by GSF on May 19, 2025. It is meant to help protect group members by limiting damages in some antitrust cases. The Act only allows antitrust plaintiffs to get actual damages in specific situations. No other changes were made to the group’s membership or planned activities. Membership in GSF is still open. GSF will keep submitting notifications when there are more membership changes. GSF first filed a notification with the Department of Justice on September 18, 2024. The Department published a notice about this on October 11, 2024. The last update before this one was filed on February 25, 2025, and a notice was published on March 7, 2025. Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division, signed this latest notice. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Announces Membership Changes in Subcutaneous Drug Development & Delivery Consortium, Inc. Estimated reading time: 3–5 minutes On May 23, 2025, the Subcutaneous Drug Development & Delivery Consortium, Inc. filed official notifications about changes in its group membership. This was done under section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. The notification was sent to both the Attorney General and the Federal Trade Commission. The purpose was to extend protections under the Act. These protections limit antitrust plaintiffs to actual damages in certain cases. Four new parties have joined the consortium. They are Matchstick LLC from Boonton, New Jersey; Gilead Sciences, Inc. from Forest City, California; SHL Medical AG from Zug, Switzerland; and Regeneron Pharmaceuticals, Inc. from Tarrytown, New York. No other changes were made to the membership or to the planned activities of the group research project. Membership in the research project remains open. The Consortium plans to file more notifications if there are membership changes in the future. The original notification for the Consortium was filed on October 26, 2020. The Department of Justice published a notice about this in the Federal Register on December 3, 2020 (85 FR 78148). The most recent membership update before this one was filed on October 4, 2024. A notice of that filing was published in the Federal Register on December 20, 2024 (89 FR 104209). This announcement was signed by Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division. [Federal Register, Volume 90, Number 113, Friday, June 13, 2025, Page 25081] Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DOJ Publishes Update on Rapid Response Partnership Vehicle Membership Estimated reading time: 3–5 minutes The Department of Justice Antitrust Division published a notice about changes in the Rapid Response Partnership Vehicle (RRPV) group. The notice appeared in the Federal Register on June 13, 2025. The RRPV is a group covered by the National Cooperative Research and Production Act of 1993. This law limits antitrust damages for certain group activities. The RRPV must tell the Attorney General and the Federal Trade Commission about changes in its members. On April 8, 2025, RRPV sent a written update to the proper authorities. This update shared new members joining the group and noted some leaving members. The notice lists all these changes. New Members Added Many organizations have joined the RRPV. Some new members include: Fisher BioServices, Inc., Rockville, MD Landmark Vaccines, Ltd., Loughborough, United Kingdom Rx Bandz, Locust Valley, NY Zeteo Tech, Inc., Sykesville, MD BioNet-Asia Co., Ltd, Bangkok, Thailand EmitBio, Inc., Morrisville, NC Matisse Pharmaceuticals, B.V., Geleen, Netherlands National Institute for Pharmaceutical Technology and Education, Inc., Minneapolis, MN ProtonDx, Ltd., London, United Kingdom BioVaxys Technology Corp., Etobicoke, Canada Enplas, Santa Clara, CA RHEAVITA BV, Ghent, Belgium And many more listed in the official document. The notice lists each new member, including companies from different countries and states in the United States. Members That Withdrew Some groups have left the RRPV. These include: TFF Pharmaceuticals, Inc., Fort Worth, TX Spring Discovery, Inc., San Carlos, CA Cue Health, Inc., San Diego, CA Deimos Biosciences, San Francisco, CA Other Details There were no other changes in membership or group activities. Membership in the RRPV is still open. RRPV plans to keep reporting any new changes in its membership. RRPV first filed for coverage under the antitrust law on January 5, 2024. The Department of Justice reported this in the Federal Register on April 16, 2024. The last membership update before this new one was filed on January 16, 2025 and published on February 28, 2025. The notice was signed by Suzanne Morris, Deputy Director of Civil Enforcement Operations at the Antitrust Division. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Publishes Notice on Medical CBRN Defense Consortium Membership Changes Estimated reading time: 2–3 minutes On June 13, 2025, the Department of Justice published a notice in the Federal Register about the Medical CBRN Defense Consortium (MCDC). The notice states that on April 1, 2025, the MCDC sent written notifications to the Attorney General and the Federal Trade Commission. This was done under the National Cooperative Research and Production Act of 1993. The notifications are meant to extend the law’s rules that limit antitrust plaintiffs to only actual damages in some cases. The notice lists three new members added to the MCDC: Defense Operations & Executions Solutions, Inc., W Melbourne, FL Systems & Technology Research, Woburn, MA The Trustees of the University of Pennsylvania, Philadelphia, PA No other changes have been made to the membership or planned activities of the MCDC. Membership in the group is still open. MCDC will continue to file more notifications when new members join. MCDC first filed a notification under this law on November 13, 2015. The Department of Justice published the first related notice on January 6, 2016 (81 FR 513). The last membership notification was filed on January 6, 2025. Another notice about this was published on February 28, 2025 (90 FR 10945). This most recent notice was signed by Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

New Companies Join Medical Technology Enterprise Consortium Estimated reading time: 4–6 minutes On April 7, 2025, the Medical Technology Enterprise Consortium (MTEC) filed a notification with the Department of Justice and the Federal Trade Commission. This was done under the National Cooperative Research and Production Act of 1993, section 6(a). Many new companies and organizations have been added as members of MTEC. The list includes AbViro LLC (Bethesda, MD), Advanced BioScience Laboratories, Inc. (Rockville, MD), Advanced Light Devices LLC (Las Vegas, NV), AI Optics, Inc. (New York, NY), Alamgir Research, Inc. dba ARIScience (Wayland, MA), Alcamena Stem Cell Therapeutics LLC (Halethorpe, MD), American Type Culture Collection (Manassas, VA), and BelleTorus Corp. (Cambridge, MA). The new members also include BIOPAC Systems, Inc. (Goleta, CA), Bitterroot Innovation LLC (Stevensville, MT), Business Enabled Acquisition and Technology, Inc. (San Antonio, TX), CereVu Medical, Inc. (San Francisco, CA), CleanBeam Technologies LLC (Greensboro, NC), Clearview Limited LLC dba Grant Engine (Durham, NC), Clyra Medical Technologies, Inc. (Tampa, FL), Cornell University (Ithaca, NY), CranioSense, Inc. (Bedford, MA), and DanForth Advisors (Waltham, MA). Other new members are Dephy, Inc. (Boxborough, MA), Evrys Bio LLC (Doylestown, PA), Global Resonance Technologies LLC (Shelbourne, VT), GreenLifeTech Corp. (Banner Elk, NC), Griffith University (Southport, Australia), Guide Biomedical Solutions LLC (Media, PA), Healables Digital Health, Inc. (Miami, FL), Health Helper Holdings, Inc. (Hollywood, FL), Heartland GS LLC (Delaware, OH), and Hemerus Medical LLC (St Paul, MN). The growing MTEC group also now includes Humanetics Corp. (Excelsior, MN), ICPupil, Ltd. (Tel Aviv, Israel), Innovative Design Labs, Inc. (Minneapolis, MN), IntegerBio, Inc. (Gaithersburg, MD), KBR (Houston, TX), Layer 3 Services Pty, Ltd. (Fyshwick, Australia), LumenAstra, Inc. (Boulder, CO), Matisse Pharmaceuticals, B.V. (Geleen, Netherlands), Medasense Biometrics, Ltd. (Ramat Gan, Israel), and MendaCel, Inc. (Laguna Beach, CA). Additional companies are MHCombiotic, Inc. (Calgary, Canada), Miracus LLC (Troy, MI), Molecular Technologies Laboratories dba InfinixBio (Galena, OH), Musculoskeletal Transplant Foundation, Inc. (Edison, NJ), Nanohmics, Inc. (Austin, TX), Neural Dynamics Technologies, Inc. (Newton, MA), Neurovascular Research and Design Corp. (Tucson, AZ), NextCure, Inc. (Beltsville, MD), Nostopharma LLC (Bethesda, MD), Obvius Robotics, Inc. (Sunrise, FL), Orgenesis, Inc. (Germantown, MD), pdx-tec LLC dba ppx-tec LLC (Jackson, MS), and Persistent Technology, Inc. (Alexandria, VA). More new members include President and Fellows of Harvard College (Cambridge, MA), PROYECCIÓN 22 SA DE CV (Uruapan, Mexico), Pulsethera, Inc. (Chestnut Hill, MA), Quest Consultants LLC dba Aerstone (Kensington, Morocco), Radiatric, Inc. (Washougal, WA), Results Group LLC (Glastonbury, CT), Roam Robotics, Inc. (San Francisco, CA), Safeguard Surgical (Tampa, FL), SafePush LLC (New Orleans, LA), Sciperio, Inc. (Orlando, FL), Senseye, Inc. (Austin, TX), SereNeuro Therapeutics, Inc. (Baltimore, MD), Signature Performance, Inc. (Omaha, NE), SilverStream Medical (Caesarea, Israel), Solascure, Ltd. (Cambridge, United Kingdom), Stoic Bio, Inc. (San Diego, CA), and Summit Technology Laboratory (Irvine, CA). Tillerline Associates LLC (Solon, OH), Tunnell Consulting, Inc. (Bethesda, MD), University of Arkansas for Medical Sciences (Little Rock, AR), Valinor Enterprises (Alexandria, VA), Vira Regen, Inc. (Salt Lake City, UT), and VitaKey, Inc. (Birmingham, AL) are also new parties to this group. No other changes have been made to the membership or the planned activity of the MTEC research project. Membership in this group research project remains open. MTEC will file more notifications when there are changes in membership. MTEC first filed with the Department of Justice on May 9, 2014. A notice was published in the Federal Register on June 9, 2014 (79 FR 32999). The last notification was filed on January 6, 2025, and was published on February 4, 2025 (90 FR 8943). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division, signed the notice. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Issues Notice on Corrosion Under Insulation Research Group Estimated reading time: 3–5 minutes On January 6, 2025, the Cooperative Research Group Corrosion Under Insulation–Phase 2 (CUI–Phase 2) filed written notifications with the Attorney General and the Federal Trade Commission. This was done under section 6(a) of the National Cooperative Research and Production Act of 1993. The notifications shared the names of all parties involved in the venture. These parties are: Conoco Phillips Company, Houston, TX Nanotech Inc., Houston, TX Armancell Engineered Systems Ltd., London, UNITED KINGDOM The Sherwin Williams Company, Cleveland, OH PPG Industries, Incorporated, Pittsburgh, PA International Paint LLC, Houston, TX Superior Products International II, Inc., Shawnee, KS Promat Incorporated, Maryville, TN Jotun A/S, Sandefjord, KINGDOM OF NORWAY Hempel A/S, Lyngby, KINGDOM OF DENMARK BP America Production Company, Houston, TX Air Products and Chemicals, Inc., Allentown, PA Aspen Aerogels, Inc., Marlborough, MA Exxonmobil Technology and Engineering, Spring, TX Equinor Energy AS, Stavanger, KINGDOM OF NORWAY The notice explained that these notifications were filed to use the Act’s provisions. These provisions can limit the damages recoverable by antitrust plaintiffs to actual damages in certain situations. The CUI–Phase 2 group will focus on testing protective coatings and insulation products. This includes insulative coatings using the TM21442 test method and similar methods. The tests will happen in both laboratory and field settings. Phase 2 of the project will also use laboratory setups to test new sensing technologies for Corrosion Under Insulation. Early tests will check a range of CUI sensors and compare how they perform. The test methods described above will be used. The CUI Phase 2 group has four main technical tasks: Performance testing of CUI Protective Coating/Insulation Systems Performance evaluation of CUI Insulative Coatings Performance evaluation of CUI Insulative Coatings Preliminary evaluation of CUI Sensors Suzanne Morris, Deputy Director of Civil Enforcement Operations in the Antitrust Division, signed the notice. The full notice appears in the Federal Register, Volume 90, Number 113 (Friday, June 13, 2025), on page 25080. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Notice of Changes in the Customer Experience Hub Membership Estimated reading time: 2–3 minutes On April 1, 2025, the Customer Experience Hub (CX Hub) sent new written notifications under the National Cooperative Research and Production Act of 1993. This Act is also called 15 U.S.C. 4301 et seq. These notifications were sent to both the Attorney General and the Federal Trade Commission. The purpose was to inform them of changes to CX Hub’s membership. The goal is to extend the Act’s protections that limit antitrust plaintiffs’ recovery to actual damages in certain cases. Four new organizations have joined the CX Hub: Ammonoosuc Community Health Services, Inc., Littleton, NH Merative US LP, Ann Arbor, MI Polished Technologies LLC, Chevy Chase, MD Washington State University Health Sciences, Spokane, WA Three organizations have withdrawn from the CX Hub: Ruth Health, Bronx, NY Spring Discovery, Inc., San Carlos, CA The Innovation Foundation at Oklahoma State University, Inc., Stillwater, OK No other changes were made to the group’s membership or planned activity. Membership in the CX Hub remains open. CX Hub will continue to file notifications about any membership changes. CX Hub filed its original notification under section 6(a) of the Act on January 11, 2024. The Department of Justice published a notice in the Federal Register on April 16, 2024 (89 FR 26929). The last notification was filed with the Department on January 3, 2025. A notice was published in the Federal Register on February 4, 2025 (90 FR 8942). This notice is issued by Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division, Department of Justice. [FR Doc. 2025-10816 Filed 6-12-25; 8:45 am] BILLING CODE P Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Announces Proposed Consent Decree Amendment for Youngstown, Ohio Estimated reading time: 5–8 minutes On June 6, 2025, the Department of Justice lodged a proposed Consent Decree Amendment with the United States District Court for the Northern District of Ohio. The case is titled United States et al. v. City of Youngstown, Ohio, Case No. 4:98-CV-2438. This proposed Amendment changes the Clean Water Act Consent Decree first entered in 2002. The Consent Decree and Long-Term Control Plan (LTCP) had addressed violations related to sewage and stormwater releases from the City of Youngstown’s combined sewer system. The LTCP had been approved by the U.S. EPA and the State of Ohio in 2015. The Amendment makes specific changes. First, it replaces the requirement to finish the “Wet Weather Facility Project” with a new requirement. The City must now complete the “CSO 6057 Control Measure Project.” This is an 80 million gallon per day (MGD) high-rate treatment facility. The facility will use cloth-disk filter media technology for the treatment of wet weather flows. Second, the Amendment replaces Chapter 5 of the LTCP with a new Chapter 5. This includes a Revised Implementation Schedule. The new schedule requires Youngstown to complete the “West-Division Interceptor Sewer Replacement.” This project is needed to reduce combined sewer overflows. The schedule for Phase 1 of the LTCP is changed as well. The changes set deadlines for the CSO 6057 Control Measure Project. The schedule for the “Mill Creek Project” will be compressed and accelerated. The Amendment also sets earlier deadlines to submit reports about new projects for LTCP Phase 2. There is now a 30-day public comment period on the proposed Consent Decree Amendment. Comments should be sent to the Assistant Attorney General, Environment and Natural Resources Division. Comments must mention United States et al. v. City of Youngstown, Ohio, D.J. Ref. No. 90-5-1-1-4383. Comments must be received within thirty days after June 12, 2025. Comments can be sent by email to the address listed in the notice, or by mail to: Assistant Attorney General, U.S. DOJ–ENRD, P.O. Box 7611, Washington, DC 20044-7611. Written comments may be made part of the public record. During the comment period, the full Consent Decree Amendment can be read and downloaded at: https://www.justice.gov/enrd/consent-decrees. Anyone needing help accessing the document can contact the Department of Justice by email or mail at the addresses given above. Laura Thoms, the Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division, submitted this notice. Reference: Federal Register, Volume 90, Number 112, June 12, 2025, Page 24817. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Releases Update on Utility Broadband Alliance, Inc. Membership Estimated reading time: 3–5 minutes The Department of Justice has released a notice about Utility Broadband Alliance, Inc. (UBBA) in the Federal Register on June 11, 2025. On April 16, 2025, UBBA sent notifications under section 6(a) of the National Cooperative Research and Production Act of 1993. The notifications were sent at the same time to the Attorney General and the Federal Trade Commission. The law is found at 15 U.S.C. 4301 and is known as “the Act.” The notice shows there are changes in the UBBA membership. These notifications are for the purpose of extending the Act’s rules. The Act limits antitrust plaintiffs to recovering only actual damages in certain cases. The new parties added to the UBBA group are: Actalent, Tulsa, OK Akin Gump Strauss Hauer & Feld LLP, Washington, DC Valmont Telecom, Omaha, NE Midwave Wireless, Vienna, VA Forsk US, Inc., Chicago, IL Morse Micro, Irvine, CA No other changes have been made to the group’s membership or activities. UBBA membership stays open. UBBA will send more notifications if membership changes. UBBA filed its first notice under section 6(a) of the Act on May 4, 2021. The Department of Justice published a notice in the Federal Register on June 10, 2021 (86 FR 30981). The last membership update was filed on January 17, 2025. A Federal Register notice was published about that on March 7, 2025 (90 FR 11552). The notice was signed by Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

MLCommons Association Updates Membership, Department of Justice Notice Issued Estimated reading time: 3–5 minutes On May 16, 2025, the MLCommons Association filed an official notice with the Attorney General and the Federal Trade Commission. This filing is required under section 6(a) of the National Cooperative Research and Production Act of 1993. The Act helps limit antitrust claims against members. It allows plaintiffs to collect only actual damages under certain situations. New Members Added MLCommons has added new members to its group. The following parties are now part of the organization: DataCrunch, Helsinki, Republic of Finland Nebius BV, Amsterdam, Kingdom of the Netherlands Scitix (SGP) Tech. PTE Ltd., Singapore, Republic of Singapore Persimmons, Inc., Milpitas, California The Constant Company, LLC, West Palm Beach, Florida MiTAC Computing Technology Corporation, Hsinchu, Republic of China (Taiwan) Chiara Bonfanti (individual member), Torino, Italian Republic Bhavesh Davda (individual member), Fremont, California Yongsang Park (individual member), Cupertino, California Jared Willard (individual member), Minneapolis, Minnesota Naeem Khoshnevis (individual member), Cambridge, Massachusetts Withdrawn Members Some parties have withdrawn from MLCommons. These are: Guangdong OPPO Mobile Telecommunications Corp., Ltd., DongGuan City, People’s Republic of China Neuchips Corporation, Hsinchu, Republic of China (Taiwan) VerifAI Inc, Palo Alto, California VMind Technologies, Inc., San Francisco, California Moreh Inc., Seoul, Republic of Korea NeuReality LTD., Ceaseria, State of Israel Neural Magic, Inc., Somerville, Massachusetts PowerML, Inc, Palo Alto, California UNTETHER AI, Toronto, Canada Turaco Strategy, LLC, Boulder, Colorado Membership Status and History No other changes have been made to the group’s membership or planned activities. Membership in the research project remains open. MLCommons will continue to file written notifications for all membership changes. The original notification for MLCommons was filed on September 15, 2020. The Department of Justice published this in the Federal Register on September 29, 2020. The last membership update was filed on February 26, 2025. That update appeared in the Federal Register on March 18, 2025. Notice Information This notice was published by Suzanne Morris, Deputy Director of Civil Enforcement Operations for the Antitrust Division of the Department of Justice. Federal Register Citation: 90 FR 24670, June 11, 2025. BILLING CODE 4410-11-P Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Proposes Consent Decree for Idaho Mine Cleanup Estimated reading time: 3–5 minutes On June 3, 2025, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the District of Idaho. This filing is part of a lawsuit called United States, et al. v. Nu-West Mining Inc. and Nu-West Industries, Inc., Civil Action No. 4:25-cv-00287-AKB. The case involves claims made by the United States under Sections 106 and 113(g) of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), also known as Superfund. The Superfund law deals with cleaning up hazardous waste sites. Claims are also made by the State of Idaho and the Shoshone-Bannock Tribes. The case focuses on the East Mill Dump Sub-Operable Unit (EMDSOU) at the North Maybe Mine Site in Idaho. The Consent Decree would resolve the government’s claims against the companies. The Decree would also resolve claims by Idaho and the Shoshone-Bannock Tribes under CERCLA Section 107 and 113(g)(2) for recovery of costs spent to address hazardous waste. According to the Consent Decree, the companies will perform cleanup activities at the EMDSOU. These actions are to follow the September 1, 2022, Interim Record of Decision. The companies must also pay for oversight costs to the State of Idaho, the Shoshone-Bannock Tribes, and the United States Fish and Wildlife Service. In return, the United States will not sue the companies under Sections 106 and 107(a) of CERCLA for the work agreed upon in the Consent Decree. The State and the Tribes will also not sue or take action under Sections 106 and 107(a) of CERCLA, the Idaho Environmental Protection & Health Act, the Hazardous Waste Management Act of 1983, and the Idaho Water Quality Act. The companies give the United States similar promises about not suing. The public can comment on the Consent Decree. Comments must be sent no later than thirty days after June 10, 2025. Comments should be sent to the Assistant Attorney General of the Environment and Natural Resources Division. Comments can be submitted by email or by mail. By email: “#{email}” By mail: Assistant Attorney General, U.S. DOJ–ENRD, P.O. Box 7611, Washington, DC 20044-7611 Written comments may be included in the public court docket. During the public comment period, the Consent Decree is available for review and download at: https://www.justice.gov/enrd/consent-decrees If assistance is needed to access the Consent Decree, requests can be made via the same email or mailing addresses provided. Signed, Kathryn C. Macdonald Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Requests Comments on Unfair Immigration-Related Employment Practices Complaint Form Estimated reading time: 3-5 minutes The Executive Office for Immigration Review (EOIR) of the Department of Justice (DOJ) has released a notice about the Unfair Immigration-Related Employment Practices Complaint Form, known as Form EOIR-58. EOIR plans to submit this information collection request to the Office of Management and Budget (OMB). This submission is part of the review process required by the Paperwork Reduction Act of 1995. The Department is encouraging public comments on this collection until August 4, 2025. People can comment on the following points: Is the form needed for the work of the agency? Is the estimate of the time to complete the form accurate? Is the information collected clear and useful? Can the burden on people filling out the form be reduced by using technology? What Does the Form Do? Section 274B of the Immigration and Nationality Act (INA) prohibits job discrimination based on citizenship or national origin. It also prohibits employers from taking action against someone for using their rights, or from asking workers for more or different documents than needed in a way that leads to discrimination. People who think their rights were violated can file a charge with the DOJ Immigrant and Employee Rights Section (IER). IER has 120 days to decide whether to file a complaint with the EOIR Office of the Chief Administrative Hearing Officer (OCAHO). If IER does not file, the person can file their own complaint with OCAHO using Form EOIR-58. Changes to the Form The DOJ is making updates to the form and instructions. Changes are non-substantive and aim to improve clarity, formatting, and grammar. The IER mailing address has been updated. The Privacy Act notice now mentions OCAHO’s System of Record Notice (SORN). The estimated time to complete the form has been revised. The instructions now explain differences between filing by mail and electronically, in preparation for expanded electronic filing options. Who Uses the Form? The people who use this form are individuals who want to report unfair immigration-related job practices under INA section 274B. Filling out the form is voluntary. People may also submit a complaint in writing if it meets the requirements in 28 CFR 68.7. Burden Estimates Estimated number of respondents yearly: 38 Estimated time to complete the form: 1 hour each Total annual burden: 38 hours Cost Estimates No filing fees for Form EOIR-58 Printing cost: About $15.00 per response (5 copies, average 150 pages at 10 cents per page) Postage cost (Priority Mail): About $10.10 per response Attorney cost if legal help is used: Average attorney wage is $72.67 per hour (according to U.S. Bureau of Labor Statistics) Maximum total estimated cost to the public: $3,715.26 (($15.00 + $10.10 + $72.67) x 38 responses) People who submit the form by email will not have printing or mailing costs. Most people send the form to OCAHO by U.S. mail. EOIR is working to fully implement electronic filing. Once available, this will eliminate printing and mailing costs for these forms. Contact for More Information For more details or a copy of the proposed form and instructions, contact Justine Fuga, Associate General Counsel, EOIR, at 5107 Leesburg Pike, Suite 2600, Falls Church, VA 22041, or by calling (703) 305-0265. For additional information, contact Darwin Arceo, Department Clearance Officer, Justice Management Division, Department of Justice, Two Constitution Square, 145 N Street NE, 4W-218, Washington, DC. Publication Information This notice was dated June 2, 2025, and appeared in the Federal Register on June 5, 2025, Volume 90, Issue 107, Pages 23960-23961. BILLING CODE 4410-30-P Legal Disclaimer This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Proposes New Rule: Propionyl Chloride To Become a Controlled Chemical Estimated reading time: 3–5 minutes The Drug Enforcement Administration (DEA) is planning to make a new rule about propionyl chloride. This chemical is often used to make fentanyl and related dangerous drugs. The proposed rule would list propionyl chloride as a List I chemical. This means it will be controlled under the Controlled Substances Act (CSA). Why Is Propionyl Chloride Being Controlled? Propionyl chloride is used by illegal labs to make fentanyl, fentanyl analogues, and fentanyl-like substances. These drugs have caused many overdose deaths in the United States. Fentanyl is a powerful synthetic opioid. A small amount can be deadly. The DEA says propionyl chloride is important in making these drugs because it replaces another controlled chemical, propionic anhydride, during the process. What Will Happen If the Rule Is Finalized? Everyone who makes, sells, imports, or exports propionyl chloride will have to follow CSA rules. There will not be a threshold amount. This means any amount of propionyl chloride, even a tiny amount, will be regulated. Chemical mixtures that contain any propionyl chloride will also be regulated, no matter the concentration. No automatic exemptions will be given, but companies can apply for an exemption. Comment Period Open Until July 3, 2025 The DEA is asking for comments from the public about this rule. Comments need to be sent in by July 3, 2025. People can comment online at www.regulations.gov or by mail. All comments become part of the public record, so personal information could be seen by others. How Does Propionyl Chloride Make Fentanyl? Fentanyl and related drugs are not found in nature. They are made from chemicals. Propionyl chloride is used in several steps of different methods for making fentanyl. These methods include the “Janssen,” “Siegfried,” and “Gupta” processes. In these, propionyl chloride reacts with other chemicals to make important fentanyl building blocks. Illegal labs use propionyl chloride because it is easy to get and is not currently regulated. Making it a List I chemical will make it harder for illegal labs to get the chemical. Information Gathered by the DEA The DEA got six public comments about this action. Three comments supported the rule. Three others mentioned possible problems. Some said that propionyl chloride can also be used in research labs or in making pharmaceutical or agricultural products. Some worried that controlling this chemical would make it harder and more expensive for researchers to get. Others said most people who use it already have the paperwork to buy it. What Will Be Required If the Rule Takes Effect? Registration: Anyone making, selling, importing, or exporting propionyl chloride (or mixtures with it) must register with the DEA. Records and Reports: Records of transactions must be kept for two years. Any odd transactions, losses, or thefts must be reported. Shipping: Importing or exporting must follow DEA rules. Security: Companies must provide strong controls to prevent theft or misuse. Inspections: The DEA can inspect businesses handling this chemical. Legal Risk: Doing anything with propionyl chloride that is not allowed by law is a crime. There will be a temporary 30-day exemption for people already handling propionyl chloride. During this time, they must apply for registration or exemption. Economic and Legal Effects The DEA does not expect this rule to have big costs for companies. The main cost will be registration fees ($3,699 for manufacturers and $1,850 for distributors, importers, and exporters). Companies already making opioid medicines with fentanyl should already have DEA registration. The DEA thinks very few businesses will be impacted. The rule follows all proper government and legal procedures. It does not interfere with state laws or other government powers. Next Steps The DEA is taking comments until July 3, 2025. After that, they will decide if the rule should go into effect. Contact Information For more details, contact Terrence L. Boos at the DEA (571) 362-3249. How To Comment Online: www.regulations.gov (Docket No. DEA-1189) Mail: Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, VA 22152 All comments must be sent or postmarked by July 3, 2025. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Proposes Rule to Place 4-Fluoroamphetamine in Schedule I Estimated reading time: 3–5 minutes On June 3, 2025, the Drug Enforcement Administration (DEA) announced a proposed rule to place the substance 4-fluoroamphetamine (4-FA) in Schedule I of the Controlled Substances Act (CSA). What Is 4-Fluoroamphetamine (4-FA)? 4-FA is a central nervous system stimulant. It is similar to amphetamine and methamphetamine, which are already controlled substances. 4-FA has no approved medical use in the United States. Why Is the DEA Proposing This Rule? This proposal is partly to help the United States meet its requirements under the 1971 Convention on Psychotropic Substances. The United Nations international body placed 4-FA in Schedule II of its convention in 2018. The DEA is acting to control 4-FA following these international decisions and U.S. law. What Evidence Did the DEA Review? The DEA and the Department of Health and Human Services (HHS) reviewed scientific studies, medical information, case reports, and law enforcement data. Their findings show that 4-FA: Acts like powerful stimulant drugs. Is being abused in the United States and elsewhere. Is found in illegal drug markets. Can cause serious health problems, including death. Has no accepted medical use. Details From the Scientific Review 4-FA produces effects similar to those of schedule I and II drugs such as amphetamine, methamphetamine, cocaine, and MDMA. It increases levels of certain chemicals in the brain and produces feelings of euphoria and high energy. People have taken it without medical advice, and it has been abused in many states. Law enforcement tested drug samples and found 269 reports of 4-FA in drug exhibits from January 2011 to December 2023. Most users are young adults. The drug can be taken by swallowing or snorting. 4-FA has caused emergency department visits, overdoses, and at least five deaths. Common effects include fast heartbeat, high blood pressure, headache, agitation, and fever. No studies show that it has accepted medical use or that it is safe for use with medical supervision. Proposed Rule Details If the rule is finalized, 4-FA will become a Schedule I controlled substance. This means: Only DEA-registered persons can manufacture, distribute, import, export, research, or possess 4-FA. Those who wish to handle 4-FA will need DEA registration. Those who do not register must surrender or transfer their 4-FA stock. 4-FA will need to be stored securely. Quotas will limit manufacturing. Inventories must be taken and records kept. Reports must be submitted to the DEA. Order forms must be used for transactions. Import and export rules will apply. Activities with 4-FA not allowed under the law may lead to criminal, civil, or administrative penalties. Comment Period and Hearing Requests Comments about the proposed rule must be submitted to the DEA by July 3, 2025. People may also request a hearing by that date, showing their interest and objections. Regulatory Effects This proposal will not have a big economic impact on small businesses. There is no evidence of legitimate use for 4-FA, except in some scientific research. The DEA says this rule does not add new paperwork requirements for businesses or government agencies, but existing recordkeeping rules must be followed. How to Comment Comments can be sent electronically through the Federal eRulemaking Portal at www.regulations.gov. Paper comments can be mailed to the DEA in Springfield, Virginia. All comments are part of the public record unless marked as confidential. Conclusion The DEA is proposing full control of 4-FA due to high potential for abuse and no accepted medical use. If the rule becomes final, 4-FA and related substances will be placed in Schedule I and subject to strict regulations. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

DEA Corrects Rule to Add 2-Methyl AP-237 to Schedule I Estimated reading time: 1–7 minutes On June 3, 2025, the Drug Enforcement Administration (DEA) issued a correcting amendment in the Federal Register. This update concerns the controlled substance 2-methyl AP-237. What is 2-methyl AP-237? 2-methyl AP-237 is a synthetic drug. Its full name is 1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one. It belongs to a group of drugs called synthetic opioids. These drugs can be changed in small ways in a lab to make similar versions. Why was there a correction? The DEA first published a final order on March 15, 2024. This order put 2-methyl AP-237 and its related chemical forms into Schedule I of the Controlled Substances Act. Schedule I drugs are thought to have a high chance for abuse and no approved medical use. The order said this new rule would start 30 days later, on April 15, 2024. Before this date came, the DEA published another rule about three different drugs. These drugs—etodesnitazene, N-pyrrolidino etonitazene, and protonitazene—were also put into Schedule I. Because these two rules overlapped, there was a mistake in the text about how 2-methyl AP-237 should be listed. What does the correction do? The correction fixes the list in the government rules. It adds 2-methyl AP-237 to 21 CFR 1308.11(b), which is the official list for Schedule I drugs. It also adds its special drug code number, 9664. All other parts of the rule stay the same. The correction says 2-methyl AP-237 has been in Schedule I since April 15, 2024. The change in the text does not change when the rule started. How does this affect the law? Since April 15, 2024, it has been illegal to make, sell, or have 2-methyl AP-237 without special permission. This applies to the drug and any chemical forms that are possible. Who signed this correction? The correction was signed on May 27, 2025, by DEA Acting Administrator Robert J. Murphy. Heather Achbach, DEA Federal Register Liaison Officer, submitted the document for publication. Where can you get more information? Questions can go to Dr. Terrence L. Boos at the DEA Drug and Chemical Evaluation Section. The phone number is (571) 362-3249. Summary 2-methyl AP-237 is now clearly listed as a Schedule I controlled substance. The rule has been effective since April 15, 2024. The correction fixes a technical mistake and makes the listing official and clear. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Issues Notice on Immigration Court Forms Estimated reading time: 1–3 minutes The Department of Justice (DOJ) has published a notice about its collection of information for two important forms. These forms are used in immigration cases. The forms are called EOIR-60 and EOIR-61. The forms let an attorney or representative help a person, called a “pro se respondent,” with a legal document for the Board of Immigration Appeals or the Immigration Court. This is called a “limited appearance.” It means the lawyer only helps with one document. EOIR-60 is for the Board of Immigration Appeals. EOIR-61 is for the Immigration Court. Starting in July 2024, people can file these forms online using the EOIR Courts and Appeals System Respondent Access Portal (RAP). The forms have been updated. They no longer need to be mailed only. The EOIR Policy Manual now gives filing instructions. The new forms also let people show if they sent the paperwork to the other side electronically through ECAS. A change was made to the privacy notice on the forms. The correct system of records is JUSTICE/EOIR-003. More case information is now available online in English or Spanish at the EOIR Automated Case Information System. The EOIR-60 form now has a note to say that “limited appearance” is not allowed in Department of Homeland Security (DHS) proceedings that the Board controls. The DOJ asks for comments about the forms. People have 60 days, until August 4, 2025, to respond. They can give thoughts on whether the forms are needed, if the estimates of time are correct, and how to make the process easier. Here are details about the information collection: Type of Collection: The DOJ is updating and extending forms already in use. Forms: EOIR-60 (Board of Immigration Appeals) and EOIR-61 (Immigration Court). Who Fills Them Out: Individuals, attorneys, and representatives helping pro se respondents. Filling out the form is required to help with a document. Estimate of Use: About 40 people will fill out EOIR-60 each year. About 22,018 will fill out EOIR-61 each year. Time to Complete: Each form takes about 6 minutes. Total Annual Burden: 2,206 hours for everyone together. Cost: There is no fee to send in the forms. Forms can be sent online, saving postage costs. The estimated cost for a legal expert to fill out the form is $7.27 per time. The yearly cost for everyone combined is about $160,310.02. The DOJ’s contact for more information is Justine Fuga, Associate General Counsel at EOIR. People can also contact Darwin Arceo, Department Clearance Officer, for other questions. The notice was published on June 3, 2025. It is a public invitation for feedback on these forms and their collection. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Department of Justice Requests Public Comment on DEA Registration Forms Estimated reading time: 3–5 minutes On June 3, 2025, the Department of Justice (DOJ) announced a request for public comments regarding an extension of an information collection. This collection is for the Drug Enforcement Administration (DEA) registration forms. The specific forms are DEA Form 225, DEA Form 225a for renewals, and DEA Form 225b for chain renewals. The DOJ is required to obtain approval from the Office of Management and Budget (OMB) before continuing to collect this information. They must do this under the Paperwork Reduction Act of 1995. The DOJ invites public comments for 30 days, ending July 3, 2025. The public may comment on the accuracy of time estimates for the forms, suggest better ways to collect information, and more. Anyone interested can provide comments online by visiting www.reginfo.gov/public/do/PRAMain. People may search for this collection using the title or OMB Control Number 1117-0012. The forms are used as part of the Controlled Substances Act. All businesses and individuals that manufacture, distribute, import, export, research, or analyze controlled substances must register with the DEA. These records keep controlled substances secure and ensure only approved people handle them. Here are the key details: Type of Collection: Extension, without changes, of a current approval. Title: Application for Registration, Registration Renewal, Affidavit for Chain Renewal. Forms: DEA 225, 225a, 225b. Affected Groups: Businesses, not-for-profit institutions, and government agencies. Number of Respondents: 16,560 per year. Estimated Time Per Response: 0.20066 hours. Frequency: Once per year. Total Annual Time Burden: 3,323 hours. Total Annual Non-Labor Cost: $0. Obligation: Required for businesses or individuals wanting to handle controlled substances. Anyone with questions or requests for copies of the forms or instructions can contact Heather E. Achbach, Regulatory Drafting and Policy Support Section, DEA. The contact address is 8701 Morrissette Drive, Springfield, Virginia 22152, telephone (571) 776-3882, or by email. For more information, the public can contact Darwin Arceo, Department Clearance Officer, at the DOJ’s Justice Management Division in Washington, DC. This information collection will stay in effect for up to three years if approved. Renewals will occur as needed for continued authorization. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

ANI Pharmaceuticals Inc. Applies to Import Controlled Substances Estimated reading time: 1–7 minutes ANI Pharmaceuticals Inc. has asked the Drug Enforcement Administration (DEA) to approve its registration as an importer of two controlled substances: Levorphanol and Tapentadol. Levorphanol has a drug code of 9220 and is listed as a Schedule II substance. ANI Pharmaceuticals plans to import Levorphanol for distribution to customers. Tapentadol has a drug code of 9780 and is also a Schedule II substance. ANI Pharmaceuticals will only import small amounts of Tapentadol. The Tapentadol is for internal research and making reference standards. No other uses of these drugs are allowed under this registration. Only bulk manufacturers already registered for these drugs, or new applicants, may send comments or objections about ANI’s application. Comments and objections must be sent electronically through the Federal eRulemaking Portal at https://www.regulations.gov. The deadline is July 2, 2025. Anyone asking for a hearing about this application must send their written request by July 2, 2025. Requests for hearings must be sent to several DEA addresses in Springfield, Virginia. These addresses include the Hearing Clerk/OALJ, the DEA Federal Register Representative/DPW, and the Administrator. The DEA says it will approve permit applications only if ANI Pharmaceuticals’ business activity matches what is allowed under U.S. law 21 U.S.C. 952(a)(2). ANI’s authorization will not cover importing FDA-approved or non-approved finished dosage forms for sale. The notice was signed by Matthew Strait, Deputy Assistant Administrator, and published in the Federal Register on June 2, 2025. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

Veranova, L.P. Applies to Manufacture Controlled Substances in Bulk Estimated reading time: 2–3 minutes Veranova, L.P. has sent an application to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of several controlled substances. The request was made on April 17, 2025. The proposed location for manufacturing is 25 Patton Road, Pharmaceutical Service, Devens, Massachusetts 01434-3803. The company seeks to produce the following basic classes of controlled substances: Lysergic Acid Diethylamide (LSD) (Drug Code 7315), Schedule I 3,4-Methylenedioxymethamphetamine (MDMA) (Drug Code 7405), Schedule I Dimethyltryptamine (Drug Code 7435), Schedule I Amphetamine (Drug Code 1100), Schedule II Methylphenidate (Drug Code 1724), Schedule II Nabilone (Drug Code 7379), Schedule II Hydrocodone (Drug Code 9193), Schedule II Levorphanol (Drug Code 9220), Schedule II Thebaine (Drug Code 9333), Schedule II Alfentanil (Drug Code 9737), Schedule II Remifentanil (Drug Code 9739), Schedule II Sufentanil (Drug Code 9740), Schedule II The DEA states that Veranova plans to use the substances to support manufacturing and analytical testing at its other DEA-registered manufacturing facility. No other activities for these drug codes are authorized under this registration. Anyone who is a registered bulk manufacturer of these drugs, or is applying to become one, can submit comments or object to the proposed registration. Comments and objections must be sent electronically by August 1, 2025. To submit a comment, visit https://www.regulations.gov and follow the instructions. Once a comment is submitted, you will get a Comment Tracking Number as proof. Comments may not appear immediately online. A written request for a hearing about this application must also be filed by the deadline. This notice was signed by Matthew Strait, Deputy Assistant Administrator at the DEA. The official notice is document number 2025-09929 and was published in the Federal Register Volume 90, Number 104, on June 2, 2025. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.

U.S. Marshals Service Proposes Extension of Sequestered Juror Information Form Estimated reading time: 2–3 minutes On May 28, 2025, the U.S. Marshals Service (USMS) at the Department of Justice announced a proposed extension for the “Sequestered Juror Information Form” in the Federal Register (Vol. 90, No. 101, p. 22515). This notice relates to collecting information from people or households as part of the USMS’s duty to keep federal courthouses, courtrooms, and judges safe. The “Sequestered Juror Information Form” (Form USM-523A) helps Marshals Service workers plan for and react to safety needs for jurors during court cases. There will be no changes to the form compared to the currently approved version. The USMS is simply asking for an extension of the form’s use. Comments about this extension are welcome for 60 days, ending on July 28, 2025. The public or other agencies can send feedback on things such as: Whether this information collection is needed for the job of the Bureau of Justice Statistics. If the estimate for time spent and the way it is counted is correct. How the quality or understanding of the questions can be improved. How to reduce the amount of time people need to spend answering. The USMS expects about 14 people to fill out this form each year. It should take each person about 4 minutes to finish. This adds up to around 1 hour total for all 14 people each year. There is no cost burden listed for the people filling out the form. If anyone wants to send comments, give suggestions, or get more information about the form or the process, they can contact Assistant Chief Karl Slazer at the USMS Headquarters in Arlington, Virginia at 703-740-2316 or by email. For further questions, Darwin Arceo, Department Clearance Officer, can be reached at the Justice Management Division in Washington, DC. The notice was dated May 21, 2025, and signed by Darwin Arceo as the Department Clearance Officer for the Paperwork Reduction Act at the U.S. Department of Justice. Legal Disclaimer This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.